Replimune (REPL) Non-Current Receivables (2018 - 2025)
Replimune's (REPL) quarterly Non-Current Receivables came in at $799000.0 in Q3 2025, down 3.97% year-on-year from $832000.0 in Q3 2024, and up 85.38% quarter-over-quarter from $431000.0 in Q2 2025.
Replimune (REPL) Non-Current Receivables (2018 - 2025) Analysis & Trends
Replimune has disclosed Non-Current Receivables across 8 years of filings, most recently posting $799000.0 for Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Replimune | 848.00 Mn | 578.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 799,000.00 |
| Jun 30, 2025 | 431,000.00 |
| Sep 30, 2024 | 832,000.00 |
| Jun 30, 2024 | 438,000.00 |
| Sep 30, 2023 | 809,000.00 |
| Jun 30, 2023 | 402,000.00 |
| Sep 30, 2022 | 1.30 Mn |
| Jun 30, 2022 | 821,000.00 |
| Sep 30, 2021 | 1.47 Mn |
| Jun 30, 2021 | 781,000.00 |
| Sep 30, 2020 | 1.46 Mn |
| Jun 30, 2020 | 679,000.00 |
| Sep 30, 2019 | 1.21 Mn |
| Jun 30, 2019 | 613,000.00 |
| Sep 30, 2018 | 343,000.00 |
| Jun 30, 2018 | 426,000.00 |